Sales Goals and Performance - The company has set internal sales targets for 2026, which will not be disclosed externally, and is optimistic about achieving good performance based on refined operations in 2025 [2] - The sales ratio of online to offline channels has improved from 80:20 in the 2025 semi-annual report, with further details to be revealed in the 2025 annual report [2][3] - The company reported good performance during the 3.8 promotional event, aligning with expectations, and aims to enhance sales through active participation in platform activities [3] Product Development and Innovation - The company has a robust pipeline of new products for 2026, including various forms such as dressings, masks, lotions, creams, and serums, with specifics to be confirmed based on actual launches [3] - The R&D team has expanded significantly compared to early 2025, with improvements in the educational background of its members [3] Profitability and Business Strategy - The company plans to strengthen its offline business in 2026, which has a higher net profit margin compared to online sales, and is confident in achieving better overall profitability [3] - The company is considering stock incentive plans but has not set a specific timeline for implementation, with future updates to be disclosed in accordance with regulatory requirements [3] Dividend and Financial Planning - The dividend plan for the current year has not yet been determined, and stakeholders are advised to monitor announcements scheduled for April 23, 2026 [3] General Information - The investor relations activity did not involve any major information that needs to be disclosed [3]

Group 1: Online Team and Sales Channels - The company has established operational teams in Shanghai and Hangzhou to enhance online operational efficiency and profitability, focusing on interest e-commerce and shelf e-commerce respectively [2] - All existing sales channels are considered key, with dedicated teams for each channel to deepen exploration and expand new sales channels while improving profitability [3] Group 2: Pricing and Inventory Management - The company's product pricing has remained stable, with improvements in pricing stability due to sales channel optimization [3] - Inventory levels are maintained within a reasonable range, following a sales-driven production principle to ensure timely product supply and minimize operational costs and market risks [3] Group 3: New Product Development - The company has a robust pipeline for new product launches, including medical devices and functional skincare products, with a wide range of formulations and effects [3] - The sales proportion of cosmetic products has increased following the establishment of the Shanghai R&D center, enhancing the product matrix and profitability [3] Group 4: Medical Aesthetics Business - The company is actively advancing its medical aesthetics product layout, with a rich reserve of R&D projects, although future growth as a second growth curve depends on new product output and sales performance [3]

Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Group 1: Sales and Marketing Strategies - The company is actively promoting its brand and products ahead of the International Women's Day sales event, aiming for strong sales performance [2] - The company plans to launch new products across various formats, including water, lotion, cream, and essence, in addition to upgrading existing products [2] Group 2: E-commerce Operations - The company has established e-commerce teams in Harbin, Shanghai, and Hangzhou, with specific teams focusing on different platforms like Douyin and Tmall [3] - The profitability of Tmall and Douyin will be assessed after the annual report, but both platforms have shown rapid growth and alignment with company expectations [3] Group 3: Product Development and Medical Devices - The company continues to develop medical devices, focusing on both Class II and Class III products, leveraging a collaborative R&D model [3] - The company aims to enhance its medical device product matrix to improve profitability [3] Group 4: Inventory and Production Management - The company follows a sales-driven production principle to manage inventory effectively, minimizing operational costs and market risks [4] - There is no significant risk of inventory backlog due to the company's efficient production planning [4] Group 5: Future Outlook and Corporate Governance - The company has plans for stock incentives, but the timing and implementation remain uncertain [4] - The chairman currently has no plans to reduce his shareholding in the company [4]

Core Viewpoint - The company, Fulejia, announced on September 23 that its products are primarily divided into two categories: medical devices and functional skincare products, featuring a diverse range of formulations including masks, waters, serums, lotions, sprays, single-use products, and eye masks [2] Group 1 - The company offers a wide variety of product forms, which enhances its market coverage [2] - The product categories include both medical devices and functional skincare, indicating a diversified product portfolio [2]

Core Viewpoint - The company, Fulejia, is experiencing a decline in revenue and net profit for the first half of 2025, but there are signs of recovery in the second quarter due to sales channel optimization and product price adjustments [1][2]. Group 1: Financial Performance - For the first half of 2025, the company reported a revenue of 863 million yuan, a year-on-year decrease of 8.15% [1] - The net profit attributable to shareholders was 230 million yuan, down 32.54% year-on-year [1] - The net profit after excluding non-recurring gains and losses was 166 million yuan, a decrease of 48.66% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Group 2: Sales Channels and Strategies - The company has implemented a multi-channel sales strategy, integrating online and offline sales, covering major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline medical institutions and retail stores [1] - In the second quarter of 2025, the company saw a significant revenue increase of 86.68% compared to the first quarter, indicating a recovery in performance [2] - The company is focusing on optimizing offline distribution channels, with over 99% of revenue coming from the distribution model, which incurs minimal sales expenses [2] Group 3: Product Development - The company is enhancing its product line, particularly in non-patch products, with a steady increase in their revenue share [3] - The establishment of a research and development center in Shanghai is expected to accelerate product innovation and expansion [3] - The company has completed the third round of injections for a project involving humanized collagen freeze-dried fibers, which is currently in the data cleaning and report preparation stage [3]

Group 1 - The performance growth is primarily attributed to the multi-channel and multi-category layout of the Han Shu brand and the significant revenue increase from Newpage [1] - The company continues to implement a "single focus, multiple brands, globalization" strategy, establishing a multi-brand matrix consisting of "Han Shu + Newpage + Nth Curve Brands" [1] - The main brand Han Shu achieved a GMV of 3.63 billion yuan on Douyin, maintaining the top position in the beauty sales ranking on the platform, with product breakthroughs in various categories such as Hong Man Yao, Bai Man Yao, X Peptide series, and secondary throwaway products [1] Group 2 - The professional skincare brand An Min You has entered the sensitive skin market with the "Qinghao Oil AN+" ingredient, enhancing the professional skincare portfolio [1] - The company's layout in the hair care sector includes brands like Ji Fang and Han Shu Hair Care, precisely targeting the "functional hair care" and "scalp anti-aging" niche markets [1] Group 3 - The company expects its net profit for the first half of 2025 to be between 540 million yuan and 560 million yuan, representing a year-on-year growth of 30.9% to 35.8% [3] - The expected revenue for the company is between 4.09 billion yuan and 4.11 billion yuan, with a year-on-year growth of 16.8% to 17.3% [3]

Core Viewpoint - Shanghai Shangmei Cosmetics Co., Ltd. (02145) has released a positive profit forecast for the first half of 2025, indicating strong revenue and net profit growth driven by its main brand Han Shu and the second growth curve brand New Page [1][2][4] Group 1: Financial Performance - For the first half of 2025, the company expects revenue to be between RMB 4.09 billion and RMB 4.11 billion, representing a year-on-year growth of 16.8% to 17.3% [1] - The net profit is projected to reach between RMB 540 million and RMB 560 million, showing a significant year-on-year increase of 30.9% to 35.8% [1] Group 2: Brand Strategy - The company is advancing a "single focus, multi-brand, globalization" strategy, creating a multi-brand matrix that includes the main brand Han Shu and the second curve brand New Page, achieving comprehensive layout across multiple categories and price ranges [2][12] - Han Shu has achieved a breakthrough in all-channel growth, with GMV on Douyin exceeding RMB 3.63 billion in the first half of 2025, maintaining its position as the top beauty brand on the platform [4][12] Group 3: Product Innovation - The Han Shu brand has successfully launched popular products, such as the Hong Man Yao series, which sold over 14 million sets, and the Bai Man Yao series, which continues to grow in the whitening market [4][9] - New Page has shown strong growth since its launch in 2022, with a strategic upgrade targeting "effective skincare for all ages" and achieving a sales increase of 106% during the 618 shopping festival [6][12] Group 4: Competitive Advantage - The An Min You brand targets the sensitive skin segment, utilizing innovative ingredients like Qinghao Oil AN+ to provide gentle solutions, enhancing the company's competitive edge in professional skincare [9][12] - The company has established a complete innovation matrix in the hair care sector, focusing on functional hair care and scalp anti-aging products, driven by consumer demand [9][12] Group 5: Future Outlook - The company aims to achieve a strategic goal of RMB 30 billion by 2030, leveraging clear strategic planning and ongoing research investment to transition from following international brands to leading industry development [19]